Evicenter
P&T meetings

Dersimelagon (MT-7117)

Erythropoietic protoporphyria or X-linked protoporphyria

Manufacturer
LEO Pharma
Regulatory submission
NDA submitted June 2026
Last updated
100 sources

Product information and disease descriptionProduct descriptionProduct informationDrug/Drug, drug/disease interactions

Effects of other drugs on Dersimelagon

1 evidence topic · 2 sources

Verapamil and esomeprazole

“Dersimelagon exposure increased ~25% when co‐administered with verapamil, an effect not considered clinically relevant.” (opens the source at this quote in a new tab)

“Similarly, overall exposure AUC of dersimelagon was comparable following administration alone or in combination with esomeprazole; however, coadministration of esomeprazole led to a slight decrease in Cmax (fasted: 9%, 90%CI 0.77-1.07; fed: 24%, 90%CI 0.66-0.88) compared with administration of dersimelagon alone.” (opens the source at this quote in a new tab)